Newsletter | December 6, 2024

12.06.24 -- What Will The Incoming Trump Administration Mean For Drug Patents?

FROM THE EDITOR

What Will The Incoming Trump Administration Mean For Drug Patents?

Megan Chacon, a principal at Fish & Richardson and a member of the firm’s life sciences industry team, answers questions about what a second Trump administration could mean for biopharmaceutical IP and drug patents.

INDUSTRY INSIGHTS

Maturity Model For Clinical Trial Disclosure

Is your organization seeking to improve its disclosure and transparency practices? Learn about the eight key domains that are assessed by the clinical trial disclosure maturity model.

5 Tips To Improve Patient Education

Effective patient education fosters better health outcomes, emphasizing trust, and tailored materials, while innovative tools enhance comprehension, empowering patients to manage their health.

A Guide To Protein Engineering

Almost every facet of an antibody can be modified. Explore antibody humanization, the importance of affinity and function, isotype selection, and the development of bispecific and antibody-drug conjugates.

Clinical Data Platform Considerations To Lessen CRO Reliance

Discover the crucial factors necessary to evaluate clinical data platforms, leading to more streamlined and effective management of clinical trials.

How To Unlock The Secret To Repeatable, Scalable Low Turnover

This case study shares the evolution of a 10-year partnership and extrapolate the principles that create cohesive teams and minimize turnover.

Clinical Data Like You've Never Seen It Before

In a recent webinar, experts from Revvity Signals Software explored how solutions like its Spotfire platform enable better, more streamlined clinical studies.

CONTRIBUTE TO LIFE SCIENCE LEADER

Article Submission Guidelines

Think you have a good idea for an article that Life Science Leader readers would find valuable?  Read these guidelines first before submitting your idea or your article to our editorial director.